Home  »  Equity Investing   »  Gains May Be On The Menu For Moderna Inc. (MRNA)...

Gains May Be On The Menu For Moderna Inc. (MRNA)

In a news release on Monday, Moderna Inc. (MRNA) announced that Dr. Paul Burton would be taking over as head of the medical department as of July 6. Burton currently holds the position of head of medical affairs for Johnson & Johnson.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


It was announced earlier this year that Dr. ZalTaks would be leaving the company. Burton will cover for him. Dr. Burton will be a member of the American biotechnology company’s executive committee and directly report to the CEO of Moderna, Stephan Bancel, alongside the other members of the executive committee. StéphaneBancel said in a statement, “Paul’s extensive medical experience for the global pharmaceutical and biotechnology industry will greatly assist Moderna as it expands internationally and continues its journey as a trading company.”

The experience Paul brings in several therapeutic areas, and his proven track record of successfully utilizing data science and digital technologies for transformational medicine will be an asset in the effort to create a new generation of medicines for patients based on mRNA technology. The CEO of Moderna said he was eager to work with Paul.

Dr. Burton worked at Johnson & Johnson for 16 years before joining Moderna Inc. (MRNA). He has been assigned as Managing Director of Medical Affairs at Janssen Pharmaceuticals since March 2020. In this role, he oversees medical affairs strategies and execution globally.

Moderna Inc. (MRNA) shares closed yesterday’s trading session at $207.41, a -5.23% down. As of the close of the last trading session, MRNA stock was trading at $218.85. During the last trading session, MRNA’s stock price fluctuated between $198.00 and $213.4899. The number of shares exchanged was 11.74 million, greater than the company’s 50-day daily volume of 9.87 million and higher than its Year to date volume of 11.14 million. Over the past 12 months, the company’s stock has advanced 234.53%, and in the last week, the stock has fallen -5.54%. Its shares have risen by 33.22% in the past six months and 44.38% in the past three months. So far this year, the stock has returned 98.54%. Additionally, the stock is trading at a price-to-earnings ratio of 165.40.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell



100% Free. Stop Anytime. No Spam